We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Fully Automated HbA1c Analyzer Available for Inspection at AACC Annual Meeting

By LabMedica International staff writers
Posted on 02 Aug 2016

Image: The cobas c 513 high-throughput HbA1c analyzer (Photo courtesy of Roche).

Image: The cobas c 513 high-throughput HbA1c analyzer (Photo courtesy of Roche).

A fully automated, high-throughput system for HbA1c testing will be available for inspection at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Roche (Basel, Switzerland) will introduce the cobas c 513 analyzer at Booth 1301 of the Philadelphia expo. The c 513 is a fully automated, high-throughput HbA1c testing solution with a module that can reach a throughput of up to 400 determinations per hour. The reagent compartment has 60 reagent positions that can be loaded providing up to 14,000 results.

The instrument features direct results reporting, which minimizes the risk of result misinterpretation and eliminates the need for performing time-consuming, manual result interpretation. This new analyzer also offers closed tube sampling, which reduces hands-on time, prevents sample contamination, and ensures operator safety.

As the instrument is still awaiting FDA 510(k) approval, the c 513 is not currently available in the USA.

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Roche

Visit expo >

Gold Member

Quantitative POC Immunoassay Analyzer

EASY READER+

Online QC Software
Acusera 24•7

Rapid Sepsis Test

SeptiCyte RAPID

Electrolyte Analyzer

BKE-B

Latest AACC 2016 News

Channels

Clinical Chemistry

view channel

Image: New urine test provides a simple way to screen for autism in children (Photo courtesy of Andy DeLisle/ASU Knowledge Enterprise)

Urine-Based Test Shows Promise for Autism Screening in Children

Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more

Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s

Alzheimer’s disease and Parkinson’s disease are increasing as populations age, yet diagnosis remains largely symptom-driven and often occurs after irreversible brain damage has begun. Earlier detection,... Read more

Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation

The TOBY Test for Alzheimer’s Disease from TOBY, Inc. (Austin, TX, USA) has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation as an aid in the diagnosis of Alzheimer’s disease.... Read more

Molecular Diagnostics

view channel

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak

QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more

Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Hematology

view channel

Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows

Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more

Image: Direct and indirect antitumoral effects of eosinophil (Marie Gilon et al., Journal of Experimental & Clinical Cancer Research (2026). DOI: 10.1186/s13046-026-03688-5)

Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity

Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more

Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children

Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more

Image: Graphical abstract (Waclawiczek A, Leppä AM, Renders S, et al. Cell Stem Cell, 2026. doi:10.1016/j.stem.2026.04.012)

Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more

Immunology

view channel

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more

Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more

Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring

Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read more

Routine TB Screening Test May Reveal Immune Aging and Mortality Risk

Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more

Microbiology

view channel

Image: Graphical Abstract (Microbiome Research Reports: DOI:10.20517/mrr.2025.96)

Gut Microbiome Signatures Help Identify Risk of IBD Progression

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more

FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets

Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read more

New AMR Assay Supports Rapid Infection Control Screening in Hospitals

As antimicrobial resistance spreads worldwide, healthcare-associated infections are placing a growing burden on hospitals, increasing the need for faster and broader diagnostic solutions.... Read more

Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo

In eastern Democratic Republic of the Congo, communities are confronting a resurgence of Bundibugyo ebolavirus, a rarer species for which no vaccines or treatments have been approved. Ebola is a highly... Read more

Pathology

view channel

AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes

Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more

Image: Graphical Abstract (Eldad D. Shulman et al., AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology, Cell (2026). DOI: 10.1016/j.cell.2026.04.023)

Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images

Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more

AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification

Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read more

Technology

view channel

Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps

Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more

Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance

Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read more

AI-Enabled Assistant Unifies Molecular Workflow Planning and Support

Clinical laboratories and research groups face increasingly complex molecular workflows and expanding technical documentation spread across multiple systems. Fragmented digital tools can slow experiment... Read more

AI Tool Automates Validation of Laboratory Software Configuration Changes

Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read more

Industry

view channel

Werfen and Oxford Nanopore Collaborate on Transplant Assay Development

Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more

ClearNote Health to Present Pancreatic Cancer Blood Test Data at ASCO 2026

Pancreatic cancer is among the most lethal malignancies and is often detected too late for curative intervention. Individuals at elevated risk include those with new-onset type 2 diabetes, a family history... Read more

New Distribution Agreement Expands Access to CE-Marked Precision Oncology Assays

Eurobio Scientific (Les Ulis, France) has signed a distribution agreement with Canhelp Genomics (Hangzhou, China) to broaden availability of the Canhelp‑UCa and Canhelp‑Origin assays. The agreement extends... Read more

Image: Artera’s multi-modal AI platform analyzes digital pathology and clinical data to support personalized cancer management (photo courtesy of Artera)

Artera to Highlight AI-Based Cancer Risk Stratification at ASCO 2026

Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform will be featured in multiple presentations at the ASCO 2026 Annual Meeting, taking place May 29–June 2 in Chicago.... Read more